echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Is a blessing or a curse?

    Is a blessing or a curse?

    • Last Update: 2021-03-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Recently, AstraZeneca announced the withdrawal of its Imfinzi product for use in previously treated adults with locally advanced or metastatic bladder cancer indications.

    It is reported that because Imfinzi did not meet the U.

    "Imfinzi" is AstraZeneca's first immunotherapy drug.

    Urothelial carcinoma is the most common type of bladder cancer, and its morbidity and mortality account for the first place among male genitourinary system tumors.

    In May 2017, based on the safety and efficacy data of Phase I/II clinical trials, the FDA approved Imfinzi for the treatment of patients with locally advanced or metastatic urothelial cancer.

    On March 30, 2020, based on the positive results of the Phase III clinical trial CASPIAN, Imfinzi was approved in the United States as a first-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC).

    Unfortunately, in the Phase III clinical trials for patients with bladder cancer, Imfinzi, Imfinzi + tremelimumab, the first-line treatment of unresectable, stage IV (metastatic) bladder cancer patients, failed to bring significant results compared with standard treatments.

    Dave Fredrickson, Executive Vice President of AstraZeneca’s Oncology Business Unit, said: “Immunotherapy has developed rapidly in the past few years, bringing unprecedented new options to patients.

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.